Graft-versus-Host Disease (GVHD): A Comprehensive Guide

Overview

Graft-versus-Host Disease (GVHD) is a serious and potentially life-threatening complication that can occur after an allogeneic stem cell transplant or bone marrow transplant. In GVHD, the donated cells (the graft) recognize the recipient's body (the host) as foreign and attack it, leading to inflammation and damage in various organs.

Who Does GVHD Affect?

GVHD primarily affects individuals who have undergone:

• Allogeneic hematopoietic stem cell transplantation (HSCT) – where stem cells are donated by another person.
• Bone marrow transplants from a donor (related or unrelated).

It does not occur in autologous transplants (where the patient receives their own stem cells).

Prevalence

According to the National Institutes of Health (NIH):

• Acute GVHD occurs in 30–70% of allogeneic transplant recipients.
• Chronic GVHD develops in 30–50% of patients who survive beyond the first 100 days post-transplant.

The risk varies depending on factors like donor matching, patient age, and the type of transplant.

Symptoms

GVHD can be classified into acute (occurring within the first 100 days post-transplant) and chronic (developing after 100 days or persisting long-term). Symptoms vary depending on the type and severity.

Acute GVHD Symptoms

Acute GVHD primarily affects the skin, liver, and digestive tract.

• Skin:
  • Rash (often starting on the palms, soles, or ears)
  • Redness (erythema)
  • Itching or burning sensation
  • Blistering or peeling in severe cases
• Digestive Tract:
  • Nausea and vomiting
  • Severe diarrhea (sometimes bloody)
  • Abdominal pain or cramping
  • Loss of appetite
• Liver:
  • Jaundice (yellowing of the skin and eyes)
  • Dark urine
  • Elevated liver enzymes (detected via blood tests)

Chronic GVHD Symptoms

Chronic GVHD can affect multiple organs and may resemble autoimmune diseases like lupus or scleroderma. Symptoms include:

• Skin and Nails:
  • Dry, thickened, or tightened skin
  • Rash or discoloration
  • Nail changes (ridging, splitting, or loss)
  • Hair loss or thinning
• Mouth:
  • Dry mouth (xerostomia)
  • Mouth sores or ulcers
  • Sensitivity to spicy or acidic foods
  • Difficulty swallowing
• Eyes:
  • Dry, gritty, or burning sensation (similar to Sjogren’s syndrome)
  • Redness or inflammation
  • Light sensitivity
  • Blurred vision
• Lungs:
  • Shortness of breath
  • Chronic cough
  • Bronchiolitis obliterans (a serious lung condition)
• Joints and Muscles:
  • Joint pain or stiffness
  • Muscle weakness or cramping
  • Limited range of motion
• Genital Area:
  • Vaginal dryness or irritation (in women)
  • Painful intercourse
  • Scarring or narrowing of the vagina

Causes and Risk Factors

What Causes GVHD?

GVHD occurs when the donated immune cells (T-cells) recognize the recipient’s tissues as foreign and launch an immune attack. This happens because:

• The donor’s immune system is not a perfect match to the recipient’s.
• The transplanted cells contain mature T-cells that can react against the host.

Even with a well-matched donor (such as a sibling), minor genetic differences can trigger GVHD.

Risk Factors

Several factors increase the risk of developing GVHD:

• Donor Matching:
  • Poor HLA (human leukocyte antigen) matching between donor and recipient.
  • Unrelated or mismatched donors pose a higher risk than matched sibling donors.
• Patient Age: Older patients are at higher risk.
• Donor Age: Older donors increase the risk.
• Donor Type:
  • Unrelated donors or haploidentical (half-matched) donors carry higher risk.
  • Female donors who have been pregnant (due to prior sensitization to foreign antigens).
• Stem Cell Source:
  • Peripheral blood stem cells (PBSC) have a higher risk than bone marrow.
• Conditioning Regimen:
  • Intense chemotherapy or radiation before transplant can increase GVHD risk.
• Infections: Viral infections like cytomegalovirus (CMV) can trigger or worsen GVHD.

Diagnosis

Diagnosing GVHD involves a combination of clinical evaluation, laboratory tests, and sometimes biopsies. Early diagnosis is crucial for effective management.

Diagnostic Steps

1. Medical History and Physical Exam:
   • Review of transplant details (donor type, HLA matching, conditioning regimen).
   • Assessment of symptoms (rash, diarrhea, jaundice, etc.).
2. Laboratory Tests:
   • Blood tests: Complete blood count (CBC), liver function tests (LFTs), and kidney function tests.
   • Stool tests: To rule out infections (e.g., Clostridium difficile) in patients with diarrhea.
3. Biopsies:
   • Skin biopsy: To confirm skin GVHD and rule out other causes of rash.
   • Gastrointestinal biopsy: Via endoscopy or colonoscopy to assess digestive tract involvement.
   • Liver biopsy: If liver GVHD is suspected (though this is less common due to invasiveness).
4. Imaging Tests:
   • Chest X-ray or CT scan if lung involvement is suspected.
5. Scoring Systems:
   • Doctors use grading systems (e.g., Glucksberg or IBMTR criteria) to classify GVHD severity (Grade I-IV).

Treatment Options

Treatment for GVHD aims to suppress the immune response while preserving the graft’s ability to fight infections and cancer. The approach depends on the type (acute or chronic) and severity of GVHD.

Medications

• Corticosteroids:
  • Prednisone or methylprednisolone are first-line treatments for acute GVHD.
  • Doses are gradually tapered to minimize side effects (e.g., infections, osteoporosis).
• Calcineurin Inhibitors:
  • Cyclosporine or tacrolimus suppress T-cell activity.
  • Often used in combination with steroids.
• Other Immunosuppressants:
  • Mycophenolate mofetil (MMF) or sirolimus for steroid-resistant cases.
  • JAK inhibitors (e.g., ruxolitinib) – approved for steroid-refractory acute GVHD.
• Biologic Therapies:
  • Infliximab or etanercept (TNF-alpha inhibitors) for severe cases.
  • Extracorporeal photopheresis (ECP) – a procedure where blood is treated with UV light to reduce immune activity.
• Topical Treatments:
  • Steroid creams or ointments for skin GVHD.
  • Mouth rinses (e.g., dexamethasone) for oral GVHD.

Supportive Care

• Infection Prevention:
  • Antibiotics, antivirals, and antifungals to prevent opportunistic infections.
  • Regular monitoring for infections (e.g., CMV, fungal infections).
• Pain Management:
  • Pain relievers (e.g., acetaminophen, opioids for severe pain).
• Nutritional Support:
  • IV fluids or total parenteral nutrition (TPN) if diarrhea or malnutrition is severe.
  • Dietary modifications (e.g., low-residue diet for digestive GVHD).
• Physical Therapy:
  • For patients with joint or muscle involvement to maintain mobility.

Emerging Treatments

Research is ongoing for new GVHD therapies, including:

• Mesenchymal stem cells (MSCs) – to modulate immune responses.
• Ibrutinib – a Bruton’s tyrosine kinase (BTK) inhibitor approved for chronic GVHD.
• Fecal microbiota transplantation (FMT) – being studied for gut GVHD.

Living with Graft-versus-Host Disease (GVHD)

Managing GVHD requires a multidisciplinary approach involving hematologists, dermatologists, gastroenterologists, and other specialists. Here are practical tips for daily living:

Skin Care

• Use fragrance-free, hypoallergenic moisturizers (e.g., Cetaphil, Eucerin).
• Avoid hot showers; use lukewarm water.
• Wear loose, soft clothing (e.g., cotton) to reduce irritation.
• Apply sunscreen (SPF 30+) to protect sensitive skin.

Oral Care

• Use alcohol-free mouthwashes (e.g., Biotene).
• Brush teeth gently with a soft-bristled toothbrush.
• Stay hydrated and use artificial saliva sprays for dry mouth.
• Avoid acidic or spicy foods if mouth sores are present.

Eye Care

• Use preservative-free artificial tears for dry eyes.
• Wear sunglasses to reduce light sensitivity.
• Avoid dry environments; use a humidifier if needed.

Diet and Nutrition

• Eat small, frequent meals if nausea or diarrhea is present.
• Avoid high-fiber foods if digestive GVHD is active.
• Stay hydrated; drink electrolytes if experiencing diarrhea.
• Consult a dietitian for personalized meal plans.

Emotional and Mental Health

• Join support groups (e.g., BMT InfoNet).
• Seek counseling or therapy for anxiety or depression.
• Stay connected with loved ones for emotional support.

Follow-Up Care

• Attend all scheduled appointments with your transplant team.
• Monitor for signs of infection (fever, chills, unusual fatigue).
• Keep vaccinations up to date (as recommended by your doctor).

Prevention

While GVHD cannot always be prevented, certain strategies can reduce the risk:

Pre-Transplant Strategies

• Optimal Donor Selection:
  • Choose a fully HLA-matched sibling if possible.
  • Use unrelated donors with high HLA compatibility (e.g., through registries like Be The Match).
• T-Cell Depletion:
  • Removing T-cells from the graft can reduce GVHD but may increase infection or relapse risk.
• Prophylaxis Medications:
  • Post-transplant drugs like tacrolimus + methotrexate or cyclosporine + mycophenolate to prevent GVHD.

Post-Transplant Strategies

• Close Monitoring: Regular check-ups to detect early signs of GVHD.
• Infection Control:
  • Avoid crowds and sick contacts.
  • Practice good hygiene (handwashing, mask-wearing if needed).
• Gradual Tapering of Immunosuppressants: To balance GVHD prevention with immune recovery.

Complications

If left untreated, GVHD can lead to serious, sometimes life-threatening complications:

Short-Term Complications

• Severe Infections: Due to immunosuppression (e.g., bacterial, viral, or fungal infections).
• Organ Failure:
  • Liver failure (from severe hepatitis).
  • Respiratory failure (from lung GVHD).
• Malnutrition and Dehydration: From prolonged diarrhea or inability to eat.

Long-Term Complications

• Chronic Pain and Disability: From joint or muscle involvement.
• Secondary Cancers: Increased risk of skin cancer or lymphoma due to long-term immunosuppression.
• Autoimmune Disorders: GVHD can trigger other autoimmune conditions.
• Psychological Impact: Depression, anxiety, or PTSD from prolonged illness.

When to Seek Emergency Care

References and Further Reading

• Mayo Clinic – Graft-versus-Host Disease
• National Cancer Institute (NCI) – GVHD
• NIH – Graft-versus-Host Disease
• Cleveland Clinic – GVHD
• Blood Journal – GVHD Review